US 12,083,126 B2
Pharmaceutical compositions and methods for anesthesiological applications
Dennis Elias Saadeh, Brentwood, TN (US)
Assigned to MELT PHARMACEUTICALS, INC., Brentwood, TN (US)
Filed by Melt Pharmaceuticals, Inc., Nashville, TN (US)
Filed on Apr. 29, 2022, as Appl. No. 17/732,667.
Application 17/732,667 is a continuation of application No. 16/899,353, filed on Jun. 11, 2020, abandoned.
Application 16/899,353 is a continuation in part of application No. 16/250,450, filed on Jan. 17, 2019, abandoned.
Application 16/250,450 is a continuation in part of application No. 15/995,875, filed on Jun. 1, 2018, granted, now 10,391,102, issued on Aug. 27, 2019.
Application 15/995,875 is a continuation in part of application No. 15/903,529, filed on Feb. 23, 2018, granted, now 10,166,240, issued on Jan. 1, 2019.
Application 15/995,875 is a continuation in part of application No. 15/903,615, filed on Feb. 23, 2018, granted, now 10,179,136, issued on Jan. 15, 2019.
Application 15/903,529 is a continuation in part of application No. 15/184,768, filed on Jun. 16, 2016, granted, now 9,918,993, issued on Mar. 20, 2018.
Application 15/903,615 is a continuation in part of application No. 15/184,768, filed on Jun. 16, 2016, granted, now 9,918,993, issued on Mar. 20, 2018.
Claims priority of provisional application 62/182,130, filed on Jun. 19, 2015.
Prior Publication US 2022/0249510 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/551 (2006.01); A61K 31/135 (2006.01); A61K 31/138 (2006.01); A61K 31/4178 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 31/135 (2013.01); A61K 31/138 (2013.01); A61K 31/4178 (2013.01); A61K 47/38 (2013.01)] 16 Claims
 
1. A solid pharmaceutical composition formulated for buccal and/or sublingual administration comprising a therapeutically effective dose of midazolam and a therapeutically effective dose of ketamine.